---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-25-003407"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:27:12.702411+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD reports FY2024 net loss narrowed to $2.3M; license revenue up 35%

## Summary
- Net loss from continuing operations $(2.3)M, or $(0.20)/share, improved from $(7.7)M loss in 2023.
- License revenue $1.8M, up 35.3% YoY, driven by changes in sales of Mayne licensed products.
- Total operating expenses $6.5M, down 33.6% from $9.8M, due to cost cuts and transition to royalty model.
- Cash and cash equivalents $5.1M as of December 31, 2024.
- Company continues to evaluate strategic alternatives including M&A, sale of assets, or other transactions.

## SEC filing metadata
- accession: 0001013762-25-003407
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000101376225003407/0001013762-25-003407-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000101376225003407/ea0235200-8k_therap.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-25-003407
- JSON: https://secwatch.observer/filing/0001013762-25-003407.json
- Plain text: https://secwatch.observer/filing/0001013762-25-003407.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.